Open company graph database — free web & API
Login

Gene Techno Sciences Inc.

株式会社ジーンテクノサイエンス
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
19
§01

Basic information

BASIC
Head office
3-8-3 Nihonbashi Honcho, Chuo-ku, Tokyo
Chief executive
Shinya Kuribayashi
Capital
10,000,000 JPY
Employees (non-consolidated)
Employees (consolidated)
Start date
2001-03-01
End date
§02

Websites

1 DOMAINS
§03

Business

2
Biological Similarity BusinessCell Therapy Business (Regenerative Medicine)
§04

Related companies

19 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Cell Technology Inc.
Group Subsidiary
JSR Corporation
Shareholder
ORTHOREBIRTH Inc.
Daidō Group Holdings Co., Ltd.
ナノキャリア株式会社
Shareholder
Noritz Steel Co., Ltd.
Shareholder
Itochu Chemical Frontier Co., Ltd.
Shareholder
北海道大学創成研究機構
Chijuu Pharmaceutical Co., Ltd.
Shareholder
Fuji Pharmaceutical Industry Co., Ltd.
Mita Pharmaceutical Co., Ltd.
S-Quatre Inc.
Chromocenter Inc.
GPC Research Institute Inc.
Gene Design Inc.
SANWA KAGAKU KENKYUSHO CO., LTD.
Japan Regenerative Medicine Co., Ltd.
SOLA Biosciences LLC
長春長生生物科技有限責任公司(長生バイオ)
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

51 EVENTS

FoundedSources

Established Gene Techno Sciences Inc.Sources

Formed "Bio Informatics Sapporo Consortium"Sources

Established a research institute within the Hokkaido Center of the National Institute of Advanced Industrial Science and Technology to strengthen research and development of bio-new drugsSources

Received a subsidy from the Ministry of Economy, Trade and Industry for the project "Creation of Movement Disorder Models Due to Cerebellar Dysfunction"Sources

Received joint research and development subsidy for the project "Novel Gene Discovery for Disease Models for Drug Development"Sources

Recognized as "AIST Venture Company (成果創出型)" by the National Institute of Advanced Industrial Science and TechnologySources

Relocated headquarters within the research instituteSources

Licensed out anti-α9 integrin antibody to Kaken Pharmaceutical Co., Ltd. in the bio-new drug businessSources

Signed a joint development agreement with Fuji Pharmaceutical Co., Ltd. for G-CSF in the biosimilar businessSources

Licensed in G-CSF producing cells and basic production technology from Toa Pharmaceutical Co., Ltd. in the biosimilar businessSources

Relocated headquarters to Sapporo Chuo-kuSources

Relocated research institute within Hokkaido University Genetic Disease Control Research InstituteSources

Established Tokyo office in Chuo-ku, TokyoSources

ListedSources

Founded as a venture originating from Hokkaido UniversitySources

Acquired fundamental biotechnology technologySources

Started selling one biosimilar productSources

Utilized accumulated biotechnologies to engineer new valueSources

Obtained manufacturing and sales approval for G-CSF jointly developed with Fuji Pharmaceutical Co., Ltd. (launched in May 2013)Sources

Listed on the Tokyo Stock Exchange Mothers MarketSources

Entered capital and business alliance with Itochu Chemical Frontier Co., Ltd. in the biosimilar businessSources

Relocated research institute within Hokkaido University Creation Innovation Research OrganizationSources

Signed a joint development agreement with Sanwa Chemical Research Institute Co., Ltd. for Darbepoetin alpha in the biosimilar businessSources

Aiming to commercialize nucleic acid drug development platform, signed a joint nucleic acid business agreement with Gene Design Inc.Sources

Signed a capital and business alliance with ORTHOREBIRTH Inc. for research and development of artificial bones.Sources

Daidō Inko Co., Ltd. participates in capital with a view to collaboration in medical and healthcare-related businesses.Sources

Signed a basic agreement on joint development and sales of biosimilars in the cancer treatment field with Mochida Pharmaceutical Co., Ltd.Sources

Signed a basic agreement on capital and business alliance for joint development and sales of ophthalmic biosimilars with Senju Pharmaceutical Co., Ltd.Sources

Relocated Tokyo office to Chuo Ward, Tokyo.Sources

Concluded a tender offer for our common stock and a capital and business alliance agreement with Noritz Steel Group.Sources

Signed a joint business development agreement for ophthalmic biosimilars with Senju Pharmaceutical Co., Ltd.Sources

Signed a basic agreement on commercialization of biosimilars in the Chinese market with Changchun Changsheng Biological Technology Co., Ltd. (Changsheng Bio).Sources

Joined the Biosimilar Council.Sources

Contracted a capital and business alliance with Japan Regenerative Medicine Inc. (JRM) for regenerative medicine utilizing cardiac stem cells.Sources

Signed a capital and business alliance agreement with JSR Corporation.Sources

Signed a joint business development agreement for biosimilars in the cancer treatment field with Mochida Pharmaceutical Co., Ltd.Sources

Signed a joint research agreement with Juntendo University on immune tolerance induction.Sources

Signed a capital and business alliance agreement with Itochu Chemical Frontier Inc. for new biosimilar development.Sources

Business expansionSources

Challenge GTS3.0Sources

Signed a capital and business alliance agreement with NanoCarrier Inc. and Noritz Steel Co., Ltd.Sources

Signed a joint research agreement with Chromocenter Inc. to establish foundational technology for high-producing cell line construction.Sources

Signed a joint research agreement with SOLA Biosciences, LLC in the United States for establishing foundational technology for high-producing cell line construction.Sources

Started commissioned research with GPC Research Institute Inc. for high-producing cell line construction.Sources

Fully acquired Cellectronology Inc. through share exchange.Sources

Joint research and development agreement with Orthorebirth Inc. to create treatments for cleft lip and palateSources

Change of headquarters location to Chuo Ward, TokyoSources

Fully acquired Japan Regenerative Medicine Inc. through share transfer from Noritz Steel Co., Ltd.Sources

Excluded the company from consolidation scope through transfer of all shares of Certec Technology Inc.Sources

Changed company name to Kidswell Bio CorporationSources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑